The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study.
Hiroya Takiuchi
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yasutsuna Sasaki
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Tomohiro Nishina
Honoraria - Taiho Pharmaceutical
Hirofumi Yasui
Honoraria - Taiho Pharmaceutical
Kei Muro
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Akihito Tsuji
Honoraria - Taiho Pharmaceutical
Other Remuneration - Taiho Pharmaceutical
Wasaburo Koizumi
Honoraria - Taiho Pharmaceutical
Yasushi Toh
Honoraria - Taiho Pharmaceutical
Takuo Hara
Honoraria - Taiho Pharmaceutical
Yoshinori Miyata
Honoraria - Taiho Pharmaceutical